The capacity t o convert exogenous leukotriene A, to lipoxins (LXs) was investigated in platelet suspensions from patients with myeloproliferative disorders (MPD) (n = 22) and healthy control subjects (n = 14). Platelets isolated from the controls produced mainly LXA,, but also 6(S)-LXA, and the all-trans isomers of lipoxins A, and B, , as determined by highperformance liquid chromatography and computerized UV spectroscopy. In comparison t o control levels, the mean LX synthesis was significantly lower in platelets from the MPD patients (438.7 f 62.8 and 157.4 f 31.2 pmol LXA, per log platelets, respectively; mean f SEM; P = .0001). Platelets from six of the patients showed a particularly low capacity t o produce LXs, resulting in LX levels below the detection limit or less than 7% of mean control levels. Notably, all these patients were in blastic crisis of chronic myelogenous leuke-HE LIPOXINS (LXs) constitute a novel class of After activation, granulocytes6 and monocytes' release LTA, (5(6)-epoxy-7,9-truns-l1,14-c~-eicosatetraenoic acid), the common epoxide intermediate in LT formation.' This compound can be efficiently metabolized by human platelets either to cysteinyl-containing LTs (LTC,, D,, and or to LXS.'~~'' The mechanism of transcellular LX formation in mixed human platelet/granulocyte suspensions was recently further elucidated." Thus, it was shown that granulocyte-derived LTA, was transformed by platelets to 15-OH-LTA,, which was enzymatically and nonenzymatically hydrolyzed to LXs. Several lines of evidence indicated that this 15-hydroxylation was mediated by the platelet 12-lipoxygenase ( 12-LO).'13'z Deficient 12-LO activity has been reported in suspensions of platelets and bone marrow cells from patients with chronic myelogenous leukemia (CML) and other myeloproliferative disorders (MPD)."." The objective of this investigation was therefore to elucidate the LX-producing capacity of platelets derived from patients with these diagnoses. The results demonstrate an inadequate conversion of LTA, to LXs in MPD platelets and a close correlation between mia (CML). This severely deficient LX production was paralleled by a dramatically attenuated conversion of arachidonic acid to 12-HETE (12-hydroxyeicosatetraenoic acid), while the formation of HHT (12-hydroxyheptadecatrienoic acid), a product formed via the prostaglandin endoperoxide synthase pathway, was normal. In addition, longitudinal studies of CML patients showed that blastic metamorphosis was associated with a markedly reduced capability t o synthesize LXs, while this capacity improved after retransformation into a second chronic phase. The results reveal deficient LX synthesis as a novel platelet dysfunction in MPD, particularly in blastic crisis of CML in which an essentially abolished 12-lipoxygenase activity may be a general phenomenon.
The capacity t o convert exogenous leukotriene A, to lipoxins (LXs) was investigated in platelet suspensions from patients with myeloproliferative disorders (MPD) (n = 22) and healthy control subjects (n = 14). Platelets isolated from the controls produced mainly LXA,, but also 6(S)-LXA, and the all-trans isomers of lipoxins A, and B, , as determined by highperformance liquid chromatography and computerized UV spectroscopy. In comparison t o control levels, the mean LX synthesis was significantly lower in platelets from the MPD patients (438.7 f 62.8 and 157.4 f 31.2 pmol LXA, per log platelets, respectively; mean f SEM; P = .0001). Platelets from six of the patients showed a particularly low capacity t o produce LXs, resulting in LX levels below the detection limit or less than 7% of mean control levels. Notably, all these patients were in blastic crisis of chronic myelogenous leuke-HE LIPOXINS (LXs) constitute a novel class of T oxygenated arachidonic acid derivatives sharing the common structural feature of a conjugated tetraene.' Among these compounds, L m (SS,6R,lSS-trihydroxy-7,9,13-truans-114-eicosatetraenoic acid) and LXB, (5S, 14R,15S-trihydroxy-6,10,12-truns-8-cis-eicosatetraenoic acid) have been demonstrated to possess biologic activities such as bronchoconstriction, vasodilation, stimulation of protein kinase C, and inhibition of natural killer (NK) cells.' In addition, recent reports indicate actions counterregulatory to the proinflammatory effects of leukotrienes, possibly through competition at common receptor^.'.^ Thus, LXA, has been shown to inhibit leukotriene (LT) B,-induced inflammation in the hamster cheek pouch, as well as cellular and in vivo actions of LTD, in rat glomerular mesangial cells. Furthermore, both LXA, and LXB, antagonize LTBJnduced chemotactic responses in human neutrophils. However, the physiologic role of LXs in vivo is still incompletely established.
After activation, granulocytes6 and monocytes' release LTA, (5(6)-epoxy-7,9-truns-l1,14-c~-eicosatetraenoic acid), the common epoxide intermediate in LT formation.' This compound can be efficiently metabolized by human platelets either to cysteinyl-containing LTs (LTC,, D,, and or to LXS.'~~'' The mechanism of transcellular LX formation in mixed human platelet/granulocyte suspensions was recently further elucidated." Thus, it was shown that granulocyte-derived LTA, was transformed by platelets to 15-OH-LTA,, which was enzymatically and nonenzymatically hydrolyzed to LXs. Several lines of evidence indicated that this 15-hydroxylation was mediated by the platelet 12-lipoxygenase ( 12-LO).'13'z Deficient 12-LO activity has been reported in suspensions of platelets and bone marrow cells from patients with chronic myelogenous leukemia (CML) and other myeloproliferative disorders (MPD)."." The objective of this investigation was therefore to elucidate the LX-producing capacity of platelets derived from patients with these diagnoses. The results demonstrate an inadequate conversion of LTA, to LXs in MPD platelets and a close correlation between mia (CML). This severely deficient LX production was paralleled by a dramatically attenuated conversion of arachidonic acid to 12-HETE (12-hydroxyeicosatetraenoic acid), while the formation of HHT (12-hydroxyheptadecatrienoic acid), a product formed via the prostaglandin endoperoxide synthase pathway, was normal. In addition, longitudinal studies of CML patients showed that blastic metamorphosis was associated with a markedly reduced capability t o synthesize LXs, while this capacity improved after retransformation into a second chronic phase. The results reveal deficient LX synthesis as a novel platelet dysfunction in MPD, particularly in blastic crisis of CML in which an essentially abolished 12-lipoxygenase activity may be a general phenomenon. 0 1991 by The American Society of Hematology.
severely deficient LX synthesis and decreased 12-LO activity.
MATERIALS AND METHODS
Clinical material. Blood samples were obtained from 13 patients with CML, six with polycythemia vera (PV), three with essential thrombocytosis (ET), and 14 healthy volunteers. All samples were collected with the informed consent of involved individuals in accordance with the approval of the project from the Ethics Committee of Karolinska Institutet. The clinical and laboratory characteristics of the CML patients are shown in Table 1 . Two of the patients in chronic phase ("B" and "D") were Philadelphia chromosome (Ph) negative, but both displayed low leukocyte alkaline phosphatase (LAP) scores and a typical morphologic blood and bone marrow picture compatible with the CML diagnosis. Patient "D" also presented with a moderate myelofibrosis. Clinical characteristics of CML patients in blastic crisis are described in Results. None of the patients with PV or ET received any cytoreductive therapy or nonsteroidal anti-inflammatory drugs (NSAID) within 2 weeks before testing, except one ET patient regularly taking 500 mg aspirin twice weekly. All healthy volunteers were without medication. The dihydroxy acid S(S),12(S)-DHETE was biosynthesized as described.I8 LXA, and B, were purchased from Cayman Chemical Co (Ann Arbor, MI), while 6(S)-LXA, and all-trans isomers of LXA, and B, were kindly provided by Dr K.C. Nicolaou (University of Pennsylvania, Philadelphia). All solvents of high-performance liquid chromatography (HPLC) grade were from Rathburn Chemicals Ltd (Walkerburn, Scotland).
Peripheral blood samples were obtained through venepuncture and collected in tubes containing EDTA (77 mmol/L, 7.5% volivol). After initial centrifugation at 200g for 15 minutes, the platelet-rich plasma was collected and centrifuged at 650g for 20 minutes. The platelet-containing pellet was washed twice in Tris-buffered saline containing 6.2 mmol EDTA/L and resuspended in phosphate-buffered saline (PBS; Dulbecco's formula, containing 0.89 mmol Ca2+/L, pH 7.4). White blood cells were isolated by dextran sedimentation and hypotonic ammonium chloride lysis of the remaining erythrocytes. Granulocytes were further purified by centrifugation on sodium metrizoate (Lymphoprep). The cell preparations were finally resuspended in PBS. The purity of cell suspensions was determined by phase contrast microscopy. Platelet suspensions contained less than 1 granulocyte per 2 x lo4 platelets, and granulocyte suspensions contained more than 98% granulocytes with a platelet contamination of less than 0.5 platelets per granulocyte.
All incubations (0.5 or 1.0 mL) were performed in duplicate at 37°C after 5 minutes of preincubation. Pure platelet suspensions (approximately 200 x lo6 platelets/mL) were incubated for 30 minutes with LTA, in the presence of ionophore A23187 to study LX synthesis or with arachidonic acid to study 12-HETE and HHT formation. Platelet
Preparation of cells.
Incubation procedure andproduct identification.
LT production was determined after incubation with LTA, for 5 minutes. Mixed suspensions of platelets and granulocytes (approximately 450 X lo6 platelets and 15 x lo6 granulocytes per mL) and white blood cell suspensions (15 x lo6 leukocytesimlwith contaminating platelets) were incubated for 5 or 30 minutes with ionophore A23187 to study formation of LXs and LTs, respectively. LTA,, arachidonic acid, and ionophore A23187 were used at 4,75, and 1 p"l/L, respectively, unless otherwise indicated, Human serum albumin (0.3 mgimL) was included in all incubations containing exogenous LTA,. The reactions were discontinued by the addition of 5 vol of ethanol. Cells from patients were always tested in parallel with cells from healthy controls.
After removal of precipitated material by centrifugation, the supernatant was evaporated, dissolved into appropriate mobile HPLC phase, and subjected to reverse phase HPLC. LXs were analyzed on an Ultrasphere-ODS column (4.6 x 250 mm; Beckman, San Ramon, CA) eluted with methanoliwateriacetic acid (60:40:0.01, volivol) at a flow rate of 1.0 mL/min. The identities of biosynthetic LXA,, LXB,, and 6(S)LXA, were further confirmed by rechromatography on a Nova-Pak C,, Radial-Pak (5 x 100 mm; Waters Assoc, Milford, MA) eluted with acetonitrileiwateriacetic acid (29:71:0.01, volivol) at a flow rate of 1.0 mLimin. Analyses of HETEs and LTs were performed on a Nucleosil 120-3 C,, column (3 x 100 mm; Macherey-Nagel, Diiren, Germany) eluted with methanoliwaterlacetic acid (72:28:0.01, volivol) or with acetonitrile/methanol/water/acetic acid (29:19:52: 1, vol/vol, apparent pH 5.6), respectively, at a flow rate of 0.4 mlimin. On-line product quantitation was performed using a computerized diode array spectrophotometer (HP 8451A, Hewlett Packard, Los Angeles, CA) or a variable wavelength UV-detector (LDC Spectromonitor 111; Laboratory Data Control, Stone, UK) connected to an integrator (LDCiMilton Roy IC-1OB). Products were identified by cochromatography with synthetic standards and on-line UV spectroscopy. The following extinction coefficients were used for quantitation: LXs, 50,000; 12-HETE, 27,000; HHT, 33,400; LTB, and 5(S),12(S)-DHETE, 51,000; LTC,, D,, and E,, 40,000. These systems permitted detection of LO products in the low picomolar range. The mean spread between duplicates was less than ?7%.
Mean and standard error of the mean (SEM) were used as measures of location and spread. Comparison of groups of
Statistics.
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RESULTS
Conversion of exogenous LTA, to U s and LTC, in platelet suspensions. Platelets from healthy volunteers consistently transformed LTA, to LXs, with LXA, as the major metabolite (438.7 -I-62.8 pmol LXA, per lo9 platelets; mean f SEM, n = 14; see Fig 2A) . In addition, 6(S)-LXA, and the all-trans isomers of lipoxins A, and B, were formed. A representative HPLC chromatogram obtained with normal platelets is displayed in Fig 1 (upper panel) .
Platelets from the MPD patients showed a significantly decreased capacity to convert LTA, to LXs (157.4 f 31.2 pmol LXA, per 10' platelets; n = 24; P = .0001; Fig 2A) .
Six of the patients were in blastic crisis of CML. Platelets from all these individuals, but none of the others, displayed a markedly suppressed synthesis of LXs resulting in nondetectable amounts (n = 4) or less than 7% of mean control LXA, levels (n = 2). After exclusion of blastic crisis patients from the MPD group, the mean LXA, formation was still significantly reduced (P = .0008). A chromatogram obtained with platelets from one of the CML patients in blastic crisis is shown in Fig 1 (lower panel) . The peripheral platelet counts of the patients did not correlate with the ability to produce LXs in vitro (Table 1) . Formation of LTC, from LTA, was determined in platelet suspensions from two CML patients with deficient LX synthesis (producing nondetectable levels of LXs and 93.3 pmol LXA, per 10' platelets, respectively). Both these patients readily converted LTA, to LTC, (1,156 and 873 pmol LTC, produced per lo9 platelets, respectively, as compared with a mean value of 933 f 114 pmol LTC, per lo9 platelets in six healthy control subjects). The results indicate an intact LTC, synthase activity in the platelets of these CML patients.
Conversion of exogenous arachidonic acid to 12-HETE and HHT in platelet suspensions. The six CML patients in blastic crisis with severely impaired ability to form LXs also showed a dramatically decreased capacity to convert arachidonic acid to 12-HETE (2.5 f 1.1 as compared with 81.5 f 13.1 nmol 12-HETE per lo9 platelets in controls; n = 13; P = .0006). Representative chromatograms obtained with platelets from one of the CML patients in blastic crisis and one of the healthy controls are displayed in Fig 3. The mean 12-HETE formation of the entire MPD group (n = 22; Fig 2B) was moderately reduced (47.8 2 13.9 nmol per 10' platelets; P = .015). However, after exclusion of the patients with blastic crisis from the MPD group, the 12-HETE synthesis of the remaining patients was not significantly decreased (64.9 2 17.4 nmol per lo9 platelets).
In contrast to the reduced 12-HETE formation, comparable amounts of HHT were formed in platelets from MPD patients in general, CML patients in blastic crisis, and controls (9.5 f 1.6, 9.0 f 3.1, and 7.9 ? 1.1 nmol HHT per 10' platelets, respectively). This result suggests normal platelet prostaglandin endoperoxide synthase (formerly denoted cyclooxygenase) activities in the platelets from patients with MPD, including CML patients in blastic crisis.
Formation of lipoxygenase products by mixed cell suspensions. Ionophore A23187-stimulated mixed suspensions of normal platelets and granulocytes produced both LXA, and LXB, as well as LX isomers. In contrast, autologous platelet/granulocyte suspensions from two CML patients in chronic phase and one in accelerated phase produced markedly decreased or nondetectable amounts of LXs (Fig  4) . However, when granulocytes from these patients were mixed with allogeneic control platelets, LXs were formed in amounts equal to those of autologous control incubations (Fig4). Furthermore, white blood cell suspensions (containing leukocytes and residual platelets) from all six CML patients in blastic crisis synthesized both LTB, and LTC, in normal or increased amounts. In contrast, 5(S),12(S)-DHETE, the double dioxygenation product formed by the leukocyte 5-LO and platelet 12-L0,'*." was not detected in these incubations (data not shown). Lipoxin formation and clinical characteristics of patients with CML in blastic crisis. Clinical characteristics and platelet LXA, formation of all CML patients are shown in Table 1 . Six patients fulfilled the criteria of blastic crisis ("H" through "M"), all of the myeloid type. Four of these six patients were studied on repeated occasions during the course of the disease. The severely reduced capacity to synthesize LXs and 12-HETE was consistent irrespective of ongoing treatment or peripheral platelet counts. Five patients were studied at least once during blastic crisis at a time when no chemotherapy or NSAID medication had been taken for 2 weeks before testing.
n-
Patient "H" was a woman first examined off treatment in chronic phase 1 year after diagnosis. She was studied a second time 7 months later after transformation to blastic crisis. At that time, the produced levels of LXs and 1ZHETE were less than 3% of those obtained at the first examination, while the HHT formation remained unaltered.
Patient "I," a 60-year-old woman, was studied on five occasions during a 7-month period. During this time, she gradually transformed from an accelerated phase, with migrating bone pains, increasing basophil counts, and progressive myelofibrosis, into an overt blastic crisis with predominance of myeloblasts and promyelocytes and additional chromosomal abnormalities (trisomy 8, isochromosome 17). Notably, the inability to form LXs and 12-HETE was present already in the accelerated phase and was consistent and reproducible throughout the entire study interval. On one occasion, the platelets were also incubated with a higher LTA, concentration (20 p"l/L), but still no LX formation could be detected.
The third patient, "J", presented with a clinical picture of Ph-negative CML including a low LAP score, myelofibrosis, and loss of one chromosome 18. After 10 months of intermittent hydroxyurea treatment, she progressed into blastic crisis. Her platelets were analyzed 2 months later during on-going busulfan treatment (6 mg daily). Both LX and 12-HETE formation were below detection limits.
Patient "K', a young male with a chemotherapy resistant blastic crisis, was studied twice over a period of 3 months. His platelets also showed a reproducible inability to synthesize both LXs and IZHETE, while the capacity to transform arachidonic acid to HHT remained intact.
Patient "L" progressed into blastic crisis 8 years after CML was diagnosed. When studied off treatment shortly after metamorphosis, his platelets displayed a markedly decreased capacity to form LXs as well as 12-HETE.
The platelets of a 40-year-old male (patient "M") were first studied during a newly diagnosed blastic crisis. At that time no conversion of LTA, to LXs could be observed and the 12-HETE formation was markedly reduced (Fig 5) . After chemotherapy the patient entered a second chronic phase, during which the synthesis of LXs and 12-HETE was partially restored. When this patient returned into a second blastic crisis 2 months later, the LX/ 12-HETE formation was again strongly reduced. The synthesis of HHT was stable and within normal limits on all three occasions.
For Table 1 ). Platelets were examined during three phases of the disease. Incubations were performed as described in the legend to Fig 2. 
DISCUSSION
The present report describes an impaired ability of platelets from patients with MPD, including CML, to synthesize LXs from LTA,. This novel deficiency was particularly pronounced in blastic crisis of CML, as demonstrated by negligible or nondetectable LX formation. Partially reduced LX synthesis was also found in patients with PV and ET, indicating that decreased capacity to produce LXs may be a common platelet dysfunction in MPD.
The severely reduced LX production in platelets from CML patients with blastic crisis was paralleled by an almost abolished conversion of arachidonic acid to 12-HETE. In accordance, white blood cell suspensions (containing residual platelets) from these patients failed to produce the double dioxygenation product 5(S)12(S)-DHETE, while this compound constituted a major metabolite in control incubations. The findings reveal an abrogated 12-LO activity in platelets from CML patients in blastic crisis and provide further evidence for the involvement of this enzyme in LX formation."." Previous findings indicate that partially deficient platelet 12-LO is a frequent phenomenon in MPD.I3-l5 In agreement, we observed a significantly reduced mean production of 12-HETE in MPD patients in general. However, although the platelet LX production was still significantly reduced in our remaining MPD patients (ie, results from patients in blastic crisis excluded) we were not able to clearly show a parallel impairment of 12-HETE formation in these patients. This discrepancy may be explained by the high concentration of arachidonic acid used in our experiments, because an excess of substrate may have masked a partial enzyme deficiency.
The finding of a close relation between severely deficient LX formation and blastic crisis of CML was convincingly supported also by longitudinal studies of individual patients. Thus, when one of the patients transformed from blastic crisis to a second chronic phase, a partial restoration of the capacity to synthesize LXs was observed. This capacity was again drastically reduced after retransformation into a second blastic crisis (Fig 5) . In another patient, metamorphosis to blastic crisis was associated with an almost total suppression of LX formation.
Interestingly, the present results indicate deficient platelet LX production as an early sign of metamorphosis in CML. Thus, repeated investigations of platelets obtained from a patient during a gradual transformation from accelerated phase into blastic crisis displayed a constant inability to synthesize LXs.
Some of the platelet samples used in this investigation were collected from CML patients during ongoing chemotherapy. Drugs like busulfan, hydroxyurea, and a-interferon may theoretically affect the platelet LX formation. However, five of six patients in blastic crisis were also studied during chemotherapy-free intervals, and were then shown to have equally suppressed LX synthesis as under medication (Table 1 ). This finding indicates that the impaired LX formation is linked to disease-related mechanisms rather than to given cytotoxic drugs. In agreement, a previous report showed consistently low 12-LO activity in MPD platelets obtained before, during, or after busulfan medication. 20 In contrast to the reduced platelet 12-LO activity, other enzymatic capacities involved in eicosanoid metabolism appeared intact in platelets and leukocytes from MPD patients. Thus, a normal conversion of arachidonic acid to HHT was observed also in platelets from patients in blastic crisis. This result indicates an adequately retained platelet prostaglandin endoperoxide synthase pathway. Furthermore, because HHT and thromboxane (TX) A2 are stoiciometrically formed by a common enzyme, the TX synthase:' the results suggest an intact TX production in these platelets. In agreement, platelets from 15 out of 18 MPD patients with deficient 12-LO were reported to produce normal and equimolar amounts of HHT and TXB,.13 An intact 5-LO pathway in leukocytes was indicated by the finding present of normal or increased ionophore-induced LT synthesis in white blood cell suspensions from patients with blastic crisis. These results are in agreement with our earlier findings of an increased capacity of CML leukocytes to produce LTC,." In addition, the observation that 12-LOdeficient CML platelets converted LTA, to LTC, shows that these platelets possess the ability to recognize LT& and indicates an active platelet LTC, synthase. A retained ability of CML granulocytes to release LT& was also demonstrated, because normal amounts of LXs were formed in mixed incubations with these granulocytes and control platelets (Fig 4) . Finally, the production of LXB, in these incubations suggests that the CML granulocytes expressed the epoxide hydrolase activity, necessary for formation of this compound. 1223 MPD are characterized by a clonal disturbance of hematopoietic stem cells, typically manifested not only in myelopoietic cells, but also in megakaryocytes and platelets. Thus, a variety of morphologic and functional platelet abnormalities have been described, eg, macrothrombocyte~,~, increased content of platelet factor 4 and P-thromboglob~line,~' both increased and decreased aggregation responses:o326 reduced ATP secretion:' etc. However, none of these in vitro abnormalities have been convincingly correlated to in vivo clinical complications, like bleedings or thrombotic events. Although it was suggested that 12-LOdeficient platelets may show an increased TX formation and facilitation of in vitro aggregati~n,'~.~~ this has not been For personal use only. on September 14, 2017. by guest www.bloodjournal.org From satisfactorily confirmed clinically by an elevated incidence of thrombosis.
Deficient platelet 12-LO activity has previously been documented in MPD.I3-l5 The present investigation extends these findings and demonstrates an essentially abolished 12-LO in platelets from CML patients in blastic crisis. The physiologic importance of 12-LO has been considered uncertain, because the biologic role of the classical products, 12-HPETE and 12-HETE, is unclear. However, the finding that the platelet 12-LO possesses the capacity to produce LXs may suggest a new role for this enzyme." Therefore, the functional relevance of a defect platelet 12-LO may be related to the biologic activities of the LXs rather than to those of 12-H(P)ETE. We have previously shown a strongly increased capacity of leukocytes and purified granulocytes from CML patients to produce LTC,." Interestingly, this compound, as well as LTB,, has been reported to stimulate human and murine myelopoiesis in A role for LTs in hematopoiesis in vivo was suggested by a recent report showing a distinct increase in urinary cysteinyl-containing LTs in cytopenic patients after administration of the hematopoietic growth factor granulocyte-macrophage colony-stimulating factor.31 It is possible that interactions between platelets normally present in large quantities in the bone marrow and myeloid cells under certain circumstances lead to production of LXs in vivo. In this context, the reported antagonistic effects of LXA, and LXB, on LT-induced biologic events'.' are of special interest. Thus, the LXs may exert a regulatory effect on LTC,-stimulated proliferation of myelopoietic stem cells. Therefore, it is tempting to speculate that a deficient LX formation may be of relevance for the uncontrolled myelopoiesis associated with MPD in general and blastic crisis of CML in particular. Furthermore, the inadequate 12-LO activity in MPD leads to decreased production of the transcellularly formed 5(S), 12(S)-DHETE,I5 a substance reported to inhibit LTB,-stimulated myelopoie~is.~~ The effect of LXs on human myelopoiesis in normal and leukemic bone marrow is currently under investigation.
